{"prompt": "['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', 'cause the subject to discontinue from study. The duration of the mitigation plan should not', 'exceed 2 weeks.', 'Topical antibiotic or antifungal can be used after consultation and at the discretion of the', 'Investigator. Systemic antifungals or antibiotics must be prescribed by the Investigator if', 'necessary to avoid risk of more serious or broader infections.', 'The following systemic treatments are prohibited:', \"Vitamin A supplements or St. John's Wort within 4 weeks prior to Visit 2 (Baseline) and\", 'until the Visit 6 (EOS) Note: Use of a multivitamin including Vitamin A is not exclusionary', 'provided it is taken as directed as on the packaging;', 'Retinoids within 12 weeks of Visit 2 (Baseline) or any other systemic therapies which are', 'intended for or may improve CI within 4 weeks of Visit 2 (Baseline) and until the Visit 6', '(EOS); and,', 'Immunosuppressive drugs, including systemic corticosteroids, within 2 weeks of Visit 2', '(Baseline) and until the Visit 6 (EOS).', 'The use of UV light is prohibited within 4 weeks prior to Visit 2 (Baseline) and until the Visit 6', '(EOS). Further, subjects should limit exposure to UV via sunlight and avoid tanning beds.', 'Subjects may not be enrolled in an investigational drug or device study or have used an', 'investigational drug or investigational device treatment within 30 days prior to Visit 2 (Baseline).', 'Any medication or vaccine (including over-the-counter or prescription medicines, vitamins, and/or', 'herbal supplements) that the subject is receiving at the time of enrollment or receives during the', 'study must be recorded on the eCRF along with:', 'Reason for use;', 'Dates of administration including start and end dates; and,', 'Dosage information including dose and frequency.', 'The Medical Monitor should be contacted if there are any questions regarding concomitant or prior', 'therapy.', '6.6', 'Dose Regimen Modification', 'Dose regimen modification is not allowed in this study, except for a structured treatment', 'interruption scheme (drug holiday) as detailed in Section 7.4.', '6.7', 'Treatment after the End of the Study', 'The Sponsor will not provide any additional care to subjects after they leave the study because', 'such care should not differ from what is normally expected for subjects with CI.', '31']['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', '7.0', 'DISCONTINUATION OF STUDY TREATMENT AND', 'SUBJECT DISCONTINUATION/WITHDRAWAI', 'See the Schedule of Activities (Section 1.2) for a list of the data to be collected at the time of', 'treatment discontinuation and follow-up and for any further evaluations that need to be completed.', '7.1', 'Pregnancy', 'Any female subject who becomes pregnant during the study must discontinue treatment. If a', 'pregnancy is reported, the Investigator should inform the Sponsor within 24 hours of learning of', 'the pregnancy and should follow the procedures outlined in Section 8.4.5 and Appendix 6.', '7.2', 'Inadvertent Enrollment', 'If a subject who does not meet enrollment criteria is inadvertently enrolled, that subject must be', 'discontinued from study treatment; and the Sponsor or Sponsor designee must be contacted.', '7.3', 'Adverse Events', 'A subject may discontinue from the study due to an SAE or AE. In that case, the procedures in', 'Section 8.4 must be followed.', 'See the Schedule of Activities (Section 1.2) for data to be collected at the time of treatment', 'discontinuation and follow-up and for any further evaluations that need to be completed.', '7.4', 'Temporary Discontinuation (Drug Interruption/Holiday)', 'A treatment interruption scheme will be allowed if a subject experiences skin adverse events or', 'LSRs during the study that may require interruption or termination of study medication. This is', 'intended to assist subjects to continue in the study if the event is likely or expected to lead to', 'discontinuation. Any subjects with a LSR (especially early during treatment) will be encouraged', 'to continue with their study medication since transient skin irritation is known to develop with', 'topical retinoids, but LSRs may also develop due to the vehicle formulation or other reasons.', 'It is desirable to make every effort to maintain subjects in the study to allow adequate assessment', 'of efficacy and safety, especially in this small dose-ranging study. If during the Treatment Phase', 'there is a persistent Grade 2 or greater adverse event, treatment can be temporarily interrupted, and', 'unscheduled visits/phone calls will be scheduled to monitor resolution. Supportive action (per', 'section 6.5) can be undertaken, if in the opinion of the Investigator the drug interruption alone will', 'not relieve the symptoms and may cause the subject to discontinue from study. As soon as the', 'LSR(s) have resolved, study medication will be restarted at a frequency of once daily for 2 weeks.', 'If treatment is tolerated at this frequency, then treatment will be increased to twice daily or as per', 'protocol. If necessary, a second drug interruption will be allowed according to the instructions', \"above, as per the Investigator's discussion and agreement with the Medical Monitor.\", '32']\n\n###\n\n", "completion": "END"}